Fast Tracked New Reviews When a sponsor requests Fast Tracked status, the FDA commits to more frequent interaction, rolling review of submitted data, and a pathway that can lead into other expedited programs; in practice Fast Tracked means earlier and more sustained conversations with reviewers, clarifications about trial design and biomarker use, and the option to submit portions of an application as they become available rather than waiting for a complete dossier. Because Fast Tracked refers specifically to a regulatory process, it’s useful to think of Fast Tracked as a set of procedural levers—more frequent meetings, written communications, rolling review—that together shorten the time between concept and potential approval while preserving the agency’s standards for safety and efficacy.
Fast Tracked New Reviews Fast Tracked works as a regulatory process through clearly defined steps that begin with a sponsor’s formal request and proceed through evaluation, designation, and sustained engagement, and understanding how Fast Tracked operates helps clarify both the responsibilities of sponsors and the expectations of the FDA. The mechanism of Fast Tracked is procedural rather than pharmacological: sponsors initiate the process by asking for Fast Tracked status, typically at or after IND submission but ideally before the pre-NDA meeting, and the FDA has a 60-day window to decide whether the product meets the two core criteria for Fast Tracked—treating a serious condition and addressing an unmet medical need; if the FDA grants Fast Tracked, the program’s mechanisms take effect in the form of scheduled meetings, rolling review eligibility, and enhanced communications. Fast Tracked’s practical steps are straightforward: after designation, sponsors and FDA staff schedule early and frequent interactions to align on development plans and trial designs, sponsors may take advantage of rolling review to submit completed sections of an NDA/BLA, and if data support it the product may move into Priority Review or Accelerated Approval pathways; Fast Tracked’s mechanism emphasizes timely exchange of information so that the agency can address deficiencies or questions early in the development lifecycle. The Fast Tracked process also integrates with other regulatory tools—the program often precedes Breakthrough Therapy designation or Priority Review but differs in evidentiary thresholds, and so the way Fast Tracked works is as a stage in a broader regulatory strategy that sponsors use to manage evidentiary risk while seeking earlier patient access. Order Now Fast Tracked Where to Buy